Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.

Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE.

Oncotarget. 2017 Aug 24;8(61):103014-103031. doi: 10.18632/oncotarget.20488. eCollection 2017 Nov 28.

2.

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.

Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, Varella-Garcia M, Tan AC, Doebele RC.

Mol Cancer Ther. 2017 Aug;16(8):1623-1633. doi: 10.1158/1535-7163.MCT-17-0008. Epub 2017 May 12.

3.

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE.

Mol Cancer Ther. 2016 Aug;15(8):1952-63. doi: 10.1158/1535-7163.MCT-15-0702. Epub 2016 May 24.

4.

Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.

Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM.

Methods. 2015 Jun 15;81:41-9. doi: 10.1016/j.ymeth.2015.03.006. Epub 2015 Mar 14.

5.

Disorder and residual helicity alter p53-Mdm2 binding affinity and signaling in cells.

Borcherds W, Theillet FX, Katzer A, Finzel A, Mishall KM, Powell AT, Wu H, Manieri W, Dieterich C, Selenko P, Loewer A, Daughdrill GW.

Nat Chem Biol. 2014 Dec;10(12):1000-2. doi: 10.1038/nchembio.1668. Epub 2014 Nov 2.

PMID:
25362358

Supplemental Content

Loading ...
Support Center